In this review, we present the molecules with benzazole groups that have been evaluated as inhibitors of BACE1, AChE, and BChE, as well as anti-Aβ aggregation, to test whether they could be useful as multitarget drugs for AD treatment. Here, BACE1 is linked to Alzheimer disease.